Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3705 extension study in isolated methylmalonic acidemia
NL-OMON60813Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Dec 2023
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mRNA-3705 in Isolated Methylmalonic Acidemia (MMA), sponsored by Moderna Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Dec 2023; status: recruiting.
02
Drugs
mRNA-3705
03
Conditions
Isolated Methylmalonic Acidemia (MMA)
Beyond the preview
Go deeper on NL-OMON60813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60813.